Ann: Investor Webinar Presentation, page-7

OncoSil's Paradigm Shift: Transition to Larger Investors and Long-Term Accumulation

Today's webinar was excellent, you can clearly see the pathway to commercialisation within 12-18 months. It goes in hand with a notable shift in OncoSil’s shareholder base recently, which I believe marks a significant paradigm change for the company’s stock dynamics. Over the past few months, it appears control and influence have transitioned away from the typical retail investor to larger institutional investors and funds. This change brings with it a completely different set of rules, strategies, and time horizons for OncoSil’s share price and overall market behaviour.

Institutional investors and funds tend to have:

• Longer-Term Views: Unlike many retail investors who might trade on short-term news or market sentiment, these larger players usually invest with a longer time horizon in mind. They’re more focused on the fundamental growth potential of OncoSil’s business over the coming years, rather than quick wins.
• Different Strategy and Timeframes: Large investors often accumulate shares gradually to establish a substantial position without sharply driving up the price. Their strategy can involve accumulating a base holding at lower price points. This approach can sometimes keep the share price in a certain range while they build their position.
• Market Influence: With greater financial power, funds can influence the stock’s liquidity and price stability. This can lead to less volatility in the short term as these investors methodically add to their holdings.
• Reduced Retail Influence: As institutional ownership grows, the day-to-day price movements caused by retail trading can diminish. Retail investors might find themselves increasingly out of the picture, leading to more stable price action dominated by the larger investors’ strategies and less by short-term retail sentiment.

What does this mean for OncoSil shareholders and potential investors?

• Stable Shareholding Base: Large investors with long-term visions can provide price stability. They’re less likely to panic sell on negative short-term news, focusing instead on the bigger picture of OncoSil’s growth trajectory.
• Potential for Gradual Price Appreciation: Once these investors accumulate enough shares at their target prices, the stock may start to reflect the company’s underlying value more accurately.
• Shift in Market Dynamics: With retail investors playing a smaller role, share price movement may no longer react sharply to everyday market chatter or minor announcements. Instead, the share price could be influenced more by major milestones and fundamental progress.

It’s important to keep in mind that with larger investors taking up a bigger chunk of OncoSil’s shares, the rules of engagement have changed:

• We may see periods where the share price seems suppressed or range-bound due to ongoing accumulation by these funds.
• Once these funds reach their desired holdings, we might see a different pattern where the share price could move more significantly based on the company’s fundamental developments and milestones.

Conclusion: OncoSil appears to be in a transitional phase where institutional investors and funds are taking centre stage. Their longer-term outlook and systematic accumulation can lead to a more stable share price over time, potentially reducing the volatility previously influenced by retail traders. For current shareholders and those considering investing, understanding this paradigm shift can be crucial. Recognising the longer-term perspectives and strategies of these larger investors might help in setting realistic expectations about OncoSil’s share price movements and future prospects.

.
.
Disclaimer: This is an observation and interpretation of market trends. It’s always advisable to conduct your own research or consult financial professionals before making any investment decisions.